Study Complete
Sponsor ID
20040132
Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis
Study Details
This study will determine whether treatment with AMG 162 can prevent lumbar spine bone loss in both early and late postmenopausal women with osteopenia, and to further test the safety and tolerability of AMG 162 in this population.
Protocol Summary
Primary Outcome Measures
Percent Change from Baseline in Lumbar Spine Bone Mineral Density at Month 24
Timeframe: Baseline and 24 Months
Secondary Outcome Measures
Percent Change from Baseline in Total Hip Bone Mineral Density at Month 24
Timeframe: Baseline and 24 Months
Percent Change from Baseline in Femoral Neck Bone Mineral Density at Month 24
Timeframe: Baseline and 24 Months
Percent Change from Baseline in Trochanter Bone Mineral Density at Month 24
Timeframe: Baseline and 24 months
Percent Change from Baseline in Distal 1/3 Radius Bone Mineral Density at Month 24
Timeframe: Baseline and 24 months
Percent Change from Baseline in Total Body (without head) Bone Mineral Density at Month 24
Timeframe: Baseline and 24 months
Percent Change from Baseline in Distal Radius Trabecular Volumetric Bone Mineral Density at Month 24
Timeframe: Baseline and 24 months
Percent Change from Baseline in Distal Radius Cortical Volumetric Bone Mineral Density at Month 24
Timeframe: Baseline and 24 months
Percent Change from Baseline in Distal Radius Total Volumetric Bone Mineral Density at Month 24
Timeframe: Baseline and 24 months
Study Documents
Study Synopsis
Available Language(s): English
Locations
No locations found.